次世代エネルギー産業・グリーン経済の国際リサーチ情報サイト

腎がん治療薬の世界市場:研究開発動向と2025年市場予測

RENAL CANCER TREATMENT: INDUSTRY ANALYSIS, R&D TRENDS AND WORLD MARKET FORECASTS 2015-2025

出版元:Visiongain(英国)出版元情報LinkIcon
発行年:2015年10月
定価 Single User License(1名様ライセンス) 1,799 GBP(英国ポンド) / Department License(5名様ライセンス) 2,999GBP/ Site License 4,999GBP / Global Site License 6,999GBP
ご請求は円換算(お見積り日TTSレート)となります。
納品形態:PDF by Email (※デジタル著作権管理/DRM設定有り)
当調査レポートは英文137ページになります。
商品コード:VGN473

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。



【レポート紹介】
腎がん治療薬の世界市場規模は2019年に56億ドルに達し、2025年にかけて成長が予測されます。特に免疫チェックポイント阻害剤は免疫療法分野において新たな時代を画するもので、腎がん患者の長期的治療成果の改善が期待されます。
当レポートでは2015年から2025年に至る腎がん治療薬の世界市場予測、セグメント別市場(血管新生阻害、mTOR阻害剤、モノクローナル抗体、免疫療法ほか)、主要製品別売上予測(Sutent (sunitinib)、Nexavar (sorafenib)、Votrient (pazopanib)等、全8ブランド)、主要国別市場などの詳細予測データと分析を掲載しています。また研究開発パイプライン(全21候補)、市場分析、リーディング企業動向などの調査解説を交えて、今後の市場機会と展望を検討していきます。

【レポート構成概要】VGN473_pic Renal Cancer Treatment.jpg
◆腎がん治療薬の世界市場予測2015-2025年

◆セグメント別市場予測2015-2025年および分析
・血管新生阻害剤
・mTOR阻害剤
・モノクローナル抗体(mAb)
・免疫療法
・ジェネリックその他

◆主要製品別、売上予測-2025および分析
(※以下8ブランド掲載)
・Sutent (sunitinib)
・Nexavar (sorafenib)
・Votrient (pazopanib)
・Inlyta (axitinib)
・Afinitor (everolimus)
・Torisel (temsirolimus)
・Avastin (bevacizumab)
・Proleukin (aldesleukin).

◆主要国別市場予測-2025年および分析
・米国
・日本
・ドイツ、フランス、英国、イタリア、スペイン
・ブラジル、ロシア、インド、中国

◆研究開発パイプライン、動向と進展
(※以下を含む、21薬剤候補)
・Lenvima (lenvatinib, Eisai)
・Opdivo (nivolumab, Bristol-Myers Squibb)
・Keytruda (pembrolizumab, Merck)
・Cometriq (cabozantinib, Exelixis)
・Tivantinib (ARQ197, ArQule/Daiichi Sankyo)
・IMA901 (Immatics Biotechnologies/Roche)
・Atezolizumab (MPDL3280A/Roche).

◆市場動向分析
・腎がん罹患率上昇
・拡販の制約となる高いコスト
・特許失効、ジェネリック薬の脅威
・併用療法と標的療法
・規制問題、承認動向
・SWOT分析、市場機会

◆リーディング企業動向
・Pfizer
・Novartis
・Roche
・Bayer Healthcare
・Bristol-Myers Squibb
・Exelixis
・Cerulean Pharma
・Merck & Co.

◆業界企業オピニオンインタビュー2本:
・WILEX
・TVAX Biomedical

◆調査結論
(全137ページ、51個のデータ表、38個のチャート類)

visiongain is a trading partner with the US Federal Government
【レポート詳細目次、データ項目一覧(List of Tables)は当ページ下を参照ください】

英文詳細目次(table of contents)

【原文詳細目次】

RENAL CANCER TREATMENT: INDUSTRY ANALYSIS, R&D TRENDS AND WORLD MARKET FORECASTS 2015-2025

Table of Contents

1. Report Overview

1.1 Global Market Overview of the Renal Cancer Treatment Market
1.2 Benefits of This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analytical Report
1.5 Who is This Report For?
1.6 Methods of the Study
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain

2. An Introduction to Renal Cancer Treatments

2.1 What is Renal Cancer?
2.2 Renal Cancer Drug Treatments
2.3 Defining the Renal Cancer Treatment Market

3. Leading Renal Cancer Drugs and Leading Companies: Profiles and Forecasts from 2015-2025

3.1 Angiogenesis Inhibitors Lead the Market
3.1.1 Sutent (sunitinib) - Pfizer
3.1.2 Nexavar (sorafenib) - Bayer/Onyx
3.1.3 Votrient (pazopanib) - Novartis
3.1.4 Inlyta (axitinib) - Pfizer
3.2 mTOR Inhibitors Are Strong Competitors
3.2.1 Afinitor/Votubia (everolimus) - Novartis
3.2.2 Torisel (temsirolimus) - Pfizer
3.3 Monoclonal Antibodies: One Drug Makes a Difference
3.3.1 Avastin (bevacizumab) - Roche
3.4 Immunotherapies: A Market to Watch
3.4.1 Proleukin (aldesleukin) - Novartis/Prometheus Laboratories
3.5 Leading Companies in the Renal Drug Treatment Market
3.5.1 Pfizer: Current Market Leader
3.5.2 Novartis: Building Up Strengths
3.5.3 Roche: Expanding Blockbuster Avastin
3.5.4 Bayer Healthcare and Onyx Pharmaceuticals
3.5.5 Other Companies of Interest
3.5.5.1 Exelixis, Bristol-Myers Squibb, Merck and Cerulean Pharma

4. Anti-Cancer Renal Treatments: World Market Outlook and Forecast 2015-2025

4.1 The World Market for Renal Cancer Treatments in 2014
4.2 Leading Renal Cancer Drug Treatments in 2014
4.3 World Revenue Forecasts 2015-2025: Changing Market Shares for the Renal Cancer Treatment Market
4.4 Leading Anti-Cancer Renal Treatment Submarkets 2015-2025
4.4.1 Angiogenesis Inhibitors Lead the Current Market
4.4.2 Monoclonal Antibodies: Avastin is a Strong Competitor
4.4.3 An Important Submarket: mTOR Inhibitors
4.4.4 Summary: Angiogenesis Inhibitors and mTOR Inhibitors Lead the Market in 2015
4.5 Drivers and Restraints of the Renal Cancer Treatment Market 2015-2025
4.5.1 Drivers of the Renal Cancer Treatment Market
4.5.2 Restraints of the Renal Cancer Treatment Market

5. Leading National Markets for the Renal Cancer Treatment Market 2015-2025

5.1 Regional Breakdown of the World Renal Cancer Treatment Market 2014
5.2 World Renal Cancer Treatment Market: Regional Forecasts 2015-2025
5.2.1 How Will Regional Market Shares Change to 2025?
5.3 The US Renal Cancer Treatment Market 2015-2025
5.3.1 The US Renal Cancer Treatment Market: Drivers and Restraints
5.4 The EU Renal Cancer Treatment Market 2015-2025
5.4.1 The Renal Cancer Treatment Market in Germany to 2025
5.4.2 The Renal Cancer Treatment Market in France to 2025
5.4.3 The Renal Cancer Treatment Market in Italy to 2025
5.4.4 The Renal Cancer Treatment Market in the UK to 2025
5.4.5 The Renal Cancer Treatment Market in Spain to 2025
5.5 The Japanese Renal Cancer Treatment Market
5.6 The Renal Cancer Treatment Market in the Emerging Market: BRIC Market Forecast 2015-2025
5.6.1 The Renal Cancer Treatment Market in China to 2025
5.6.2 The Renal Cancer Treatment Market in Brazil to 2025
5.6.3 The Renal Cancer Treatment Market in Russia to 2025
5.6.4 The Renal Cancer Treatment Market in India to 2025

6. Renal Cancer Drugs Industry: R&D Pipeline Analysis

6.1 Targeted Therapies in Development for the Treatment of Renal Cancer
6.1.1 Lenvima (lenvatinib) – Eisai Inc
6.1.2 Cometriq (cabozantinib) – Exelixis
6.1.3 Dovitinib (TKI258) - Novartis
6.1.4 Linifanib (ABT-869) – Abbott Laboratories
6.1.5 Tivozanib – Aveo Pharmaceuticals
6.1.6 BEZ235 - Novartis
6.1.7 Tivantinib (ARQ197) - Daiichi Sankyo/ArQule
6.1.8 Cediranib (AZD2171/Recentin) - AstraZeneca
6.2 Immunotherapies in Development for the Treatment of Renal Cancer
6.2.1 Opdivo (nivolumab) – Bristol-Myers Squibb
6.2.2 AGS-003 – Argos Therapeutics
6.2.3 IMA901- Immatics Biotechnologies/Roche
6.2.4 TVI-Kidney-1 – TVAX Biomedical
6.2.5 Keytruda (pembrolizumab/MK3475) – Merck & Co
6.2.6 Atezolizumab (MPDL3280A) - Roche
6.2.7 Avelumab (MSB0010718C) – Merck
6.3 Monoclonal Antibody Therapies in Development for the Treatment of Renal Cancer
6.3.1 TRC105 – Tracon Pharma
6.3.2 RENCAREX (girentuximab) - WILEX AG
6.3.3 Varlilumab (CDX-1127/ Anti-CD27) – Celldex Therapeutics
6.3.4 ASONEP (sonepcizumab/LT1009) – Lpath Inc
6.4 Novel Anti-Cancer Therapies in the Pipeline for Renal Cancer
6.4.1 CRLX101 – Cerulean Pharma
6.4.2 Entinostat (SNDX-275/MS-275) – Syndax Pharmaceuticals

7. Qualitative Analysis of the Renal Cancer Treatments Market, 2015-2025

7.1 SWOT Analysis of the Renal Cancer Treatment Market
7.1.1 Strengths and Weaknesses of the Market
7.1.2 The Increasing Prevalence of Renal Cancer
7.1.3 A Rise in Ageing Population
7.1.4 Increasing Risk Factors: Obesity and Smoking
7.1.5 The High Cost of Drug Treatments Will Limit Market Growth
7.1.6 Important Patent Expiries Are Looming
7.2 Opportunities and Threats
7.2.1 Novel Therapies: The Rise of Immunotherapy
7.2.2 Combination Therapies: An Opportunity to Improve on Existing Treatments
7.2.3 Regulations: A Hindrance for Growth of the Market

8. Research Interviews

8.1 Interview with Dr Paul Bevan, Head of R&D, WILEX, Munich, Germany
8.1.1 RENCAREX: Possible First Adjuvant Treatment of RCC
8.2 Interview with Gary Wood, PhD, Chief Science Officer, TVAX Biomedical, Kansas, USA
8.2.1 Novel Immunotherapy Treatment for Renal Cancer
8.2.2 The Challenges of Using New Therapies

9. Conclusions

9.1 The Renal Cancer Treatment Market: World Outlook from 2015
9.2 Growth Will Be Driven by an Increase in Demand
9.3 The Global Renal Cancer Treatment Market Will Continue to be Dominated by the US and the EU
9.4 Leading Renal Cancer Treatment Drug Companies
9.5 The Future of the Renal Cancer Treatment Market

List of Tables

Table 1.1 Foreign Currency Exchange Rates: 2014 Average Exchange Rate to $US
Table 2.1 Main Subtypes of Renal Cell Carcinoma
Table 3.1 Sutent Revenue Forecast ($bn), 2014-2025
Table 3.2 Nexavar Revenue Forecast ($bn), 2014-2025
Table 3.3 Votrient Revenue Forecast ($bn), 2014-2025
Table 3.4 Inlyta Revenue Forecast ($bn), 2014-2025
Table 3.5 Afinitor Revenue Forecast ($bn), 2014-2025
Table 3.6 Torisel Revenue Forecast ($bn), 2014-2025
Table 3.7 Avastin Revenue Forecast ($bn), 2014-2025
Table 3.8 Proleukin Revenue Forecast ($bn), 2014-2025
Table 3.9 Leading Renal Cancer Drug Manufacturer Revenues, 2014
Table 3.10 Pfizer: Selected Recent Collaborations
Table 3.11 Avastin: Selected Recent Combination Trials
Table 4.1 Global Market for Renal Cancer Drug Treatments: Revenues ($bn) and Market Shares (%) by Class, 2014
Table 4.2 Top Five Renal Cancer Treatment Drugs by Revenue ($bn), 2014
Table 4.3 Global Market Forecast for Renal Cancer Treatment Drugs by Class: Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2014-2019
Table 4.4 Global Market Forecast for Renal Cancer Treatment Drugs by Class: Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2020-2025
Table 4.5 Global Market Forecast for Renal Cancer Treatment Drugs by Class: Changing Market Shares (%), 2014-2025
Table 4.6 Angiogenesis Inhibitors Forecast: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2014-2025
Table 4.7 Monoclonal Antibodies Forecast: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2014-2025
Table 4.8 MTOR Inhibitors Forecast: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2014-2025
Table 4.9 Angiogenesis and mTOR Inhibitors Forecast: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2014-2025
Table 4.10 Drivers and Restraints of the Renal Cancer Treatment Market 2015-2025
Table 5.1 Regional and National Breakdown of the Renal Cancer Treatment Market: Market Sizes ($bn), Market Shares (%), 2014
Table 5.2 Forecast of Regional and National Renal Cancer Treatment Markets: Market Sizes ($bn), Annual Growth (%), CAGRs (%) 2014-2019
Table 5.3 Forecast of Regional and National Renal Cancer Treatment Markets: Market Sizes ($bn), Annual Growth (%), CAGRs (%), 2020-2025
Table 5.4 Forecast of Regional and National Renal Cancer Treatment Markets: Market Shares (%), 2014-2025
Table 5.5 Forecast of the US Renal Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 5.6 Drivers and Restraints of the US Market, 2015-2025
Table 5.7 EU Market Shares (%), 2014-2025
Table 5.8 Forecast of the EU Renal Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2014-2019
Table 5.9 Forecast of the EU Renal Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2020-2025
Table 5.10 Forecast of the German Renal Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 5.11 Forecast of the French Renal Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 5.12 Forecast of the Italian Renal Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 5.13 Forecast of the UK Renal Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 5.14 Forecast of the Spanish Renal Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 5.15 Forecast of the Japanese Renal Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 5.16 Forecast of the BRIC Renal Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 5.17 Forecast of the Chinese Renal Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 5.18 Forecast of the Brazilian Renal Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 5.19 Forecast of the Russian Renal Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 5.20 Forecast of the Indian Renal Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 6.1 Targeted Therapies in Development for Renal Cancer
Table 6.2 Lenvima: Target Molecules for Inhibition
Table 6.3 Immunotherapy Treatments in Development for Renal Cancer
Table 6.4 Monoclonal Antibody Treatments in Development for Renal Cancer
Table 6.5 Novel Treatments in Development for Renal Cancer
Table 7.1 Strengths and Weaknesses of the Renal Cancer Treatment Market, 2015-2025
Table 7.2 Opportunities and Threats in the Renal Cancer Treatment Market, 2015-2025
Table 9.1 Renal Cancer Treatment Market Forecast by Region: Market Size ($bn), Market Share (%), CAGR (%), 2014, 2019, and 2025
Table 9.2 Renal Cancer Treatment Drugs Market Forecasts by Class: Market Size ($bn), Market Share (%), CAGR (%), 2014, 2019, and 2025

List of Figures

Figure 1.1 Global Renal Cancer Treatment Market Segmentation Overview, 2014
Figure 3.1 Sutent Revenue Forecast ($bn), 2014-2025
Figure 3.2 Nexavar Revenue Forecast ($bn), 2014-2025
Figure 3.3 Votrient Revenue Forecast ($bn), 2014-2025
Figure 3.4 Inlyta Revenue Forecast ($bn), 2014-2025
Figure 3.5 Afinitor Revenue Forecast ($bn), 2014-2025
Figure 3.6 Torisel Revenue Forecast ($bn), 2014-2025
Figure 3.7 Avastin Revenue Forecast ($bn), 2014-2025
Figure 3.8 Proleukin Revenue Forecast ($bn), 2014-2025
Figure 4.1 Global Market for Renal Cancer Treatment Drugs: Market Shares by Class (%), 2014
Figure 4.2 Top Five Renal Cancer Treatment Drugs by Revenue: Market Shares (%), 2014
Figure 4.3 Global Market Forecast for Renal Cancer Treatment Drugs by Class: Market Sizes ($bn), 2014-2025
Figure 4.4 Global Market for Renal Cancer Treatment Drugs by Class: Market Shares (%), 2019
Figure 4.5 Global Market for Renal Cancer Treatment Drugs by Class: Market Shares (%), 2025
Figure 4.6 Angiogenesis Inhibitors Forecast: Revenue ($bn), 2014-2025
Figure 4.7 Monoclonal Antibodies Forecast: Revenue ($bn), 2014-2025
Figure 4.8 MTOR Inhibitors Forecast: Revenue ($bn), 2014-2025
Figure 4.9 Angiogenesis and mTOR Inhibitors Forecast: Revenue ($bn), 2014-2025
Figure 5.1 Regional and National Breakdown of the Renal Cancer Treatment Market: Market Shares (%), 2014
Figure 5.2 Forecast of Regional and National Renal Cancer Treatment Markets: Market Sizes ($bn), 2014-2025
Figure 5.3 Forecast Regional and National Renal Cancer Treatment Markets: Market Shares (%), 2019
Figure 5.4 Forecast Regional and National Renal Cancer Treatment Markets: Market Shares (%), 2025
Figure 5.5 Forecast of the US Renal Cancer Treatment Market: Market Size ($bn), 2014-2025
Figure 5.6 EU Market for Renal Cancer Treatment by Leading Country (%), 2014
Figure 5.7 Forecast of the EU Renal Cancer Treatment Market, Market Sizes ($bn), 2014-2025
Figure 5.8 Forecast of the German Renal Cancer Treatment Market: Market Size ($bn), 2014-2025
Figure 5.9 Forecast of the French Renal Cancer Treatment Market: Market Size ($bn), 2014-2025
Figure 5.10 Forecast of the Italian Renal Cancer Treatment Market: Market Size ($bn), 2014-2025
Figure 5.11 Forecast of the UK Renal Cancer Treatment Market: Market Size ($bn), 2014-2025
Figure 5.12 Forecast of the Spanish Renal Cancer Treatment Market: Market Size ($bn), 2014-2025
Figure 5.13 Forecast of the Japanese Renal Cancer Treatment Market: Market Size ($bn), 2014-2025
Figure 5.14 Forecast of the BRIC Renal Cancer Treatment Market: Market Size ($bn), 2014-2025
Figure 5.15 Forecast of the Chinese Renal Cancer Treatment Market: Market Size ($bn), 2014-2025
Figure 5.16 Forecast of the Brazilian Renal Cancer Treatment Market: Market Size ($bn), 2014-2025
Figure 5.17 Forecast of the Russian Renal Cancer Treatment Market: Market Size ($bn), 2014-2025
Figure 5.18 Forecast of the Indian Renal Cancer Treatment Market: Market Size ($bn), 2014-2025
Figure 9.1 Anti-Cancer Renal Drug Treatment Market Forecast by Class: Market Sizes ($bn), 2014, 2019, and 2025
Figure 9.2 Renal Cancer Treatment Market Forecasts by Region: Market Size ($bn), 2014, 2019, and 2025

掲載企業リスト

Companies Listed

American Cancer Society
Amgen
Argos Therapeutics
ArQule
ASCO (American Society of Clinical Oncology)
Astellas
AstraZeneca
Aveo Pharmaceuticals
Bayer Healthcare
Brazilian Unified Health System (SUS, Sistema Único de Saúde)
Bristol-Myers Squibb
Cancer Research UK
Celldex Therapeutics
Cerulean Pharma
Cetus Corporation
Chiron Corporation
CHMP (Committee for Medicinal Products for Human Use)
Commission de la Transparence
Daiichi Sankyo Group
DMC (Data Monitoring Committee)
Eddingpharm
Eisai Co
Eisai Inc (US subsidiary of Eisa Co)
EMA (European Medicines Agency)
European Commission
European Organisation for Research and Treatment and Cancer (EORTC)
Exelixis
FDA (US Food and Drug Administration)
French National Authority for Health
GSK
Immatics Biotechnologies
Kyowa Hakko Kirin
Lpath
Medarex
Merck & Co.
MHLW (Ministry of Health, Labour, and Welfare)
Mylan
National Cancer Institute
Nestlé Health Sciences
NHS (National Health Service)
NICE (the National Institute for Health and Care Excellence)
Novartis
ONO Pharmaceuticals
Onyx Pharmaceuticals (owned by Amgen)
Pfizer
Pharmstandard
Prometheus Laboratories
Roche
Syndax Pharmaceuticals
Tracon Pharma
TVAX Biomedical
United Nations
WILEX AG
Wyeth

プレスリリース

プレスリリース

Memo.png当レポートのプレスリリースは発行されておりません。

2319881.jpg国内外のスマートグリッド関連ニュース、リサーチ情報等を収集し隔週でお届けいたします。日本そして海外の企業動向、新製品、政府支援、技術開発、規格、導入事例、投資、調査発表など幅広く情報を定期配信いたします。
スマートグリッド・ニュースへLinkIcon


ニュースページへLinkIcon

資料検索

お探しの資料・レポートをキーワードで検索ください。

当サイト内の検索結果が表示されます。調査レポートは英文目次を掲載しているため、英語検索も有効です。
(ブラウザのスクリプトを有効にしないとサーチエンジンが表示されません)

お問い合わせ

2714110_0.jpg
レポートをお探しいたします。
当サイトに掲載されているレポート以外にも幅広くご提案可能です。レポートの内容に関するご質問、ご確認にも回答いたします。お気軽にお問い合わせください。